Skip to main navigation
  • Investor Home
  • News & Presentations
    News Events Presentations
  • Governance
    Governance Overview Board of Directors Leadership Our ESG Philosophy
  • Financials
    SEC Filings Quarterly Results Annual Reports
  • Stock Information
    Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
  • Resources
    Pipeline Investor FAQs Email Alerts Contact IR

Presentations


February 28, 2023
Arcutis 4th Quarter and Full Year 2022 Financial Results & Business Update
December 15, 2022
ARQT December 2022 Corporate Overview
December 12, 2022
Arcutis BioTherapeutics Phase 3 Atopic Dermatitis Topline Data Presentation
August 1, 2022
Arcutis ZORYVE FDA Approval Presentation
June 14, 2022
Seborrheic Dermatitis Phase 3 STRATUM Topline Presentation
March 28, 2022
Arcutis Investor Day Presentation
February 1, 2021
DERMIS-1/DERMIS-2 Phase 3 Plaque Psoriasis Topline Data Review
December 9, 2020
Arcutis 2020 Virtual Investor Day
November 23, 2020
Phase 2b Study of Roflumilast Foam in Adolescents and Adults with Scalp and Body Psoriasis
September 29, 2020
Arcutis Roflumilast Foam Seb Derm Trial and Data Infographic
  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Print Page
RSS Feeds
Email Alerts
Search
Arcutis Biotherapeutics logo
  • Contact

 (805) 418-5006
 emcintyre@arcutis.com

  • Legal Disclaimer
  • Privacy Notice
  • Cookie Settings

Social Links

  • LinkedIn
  • Twitter
© 2023 Arcutis Biotherapeutics